This technology is the identification of an oncometabolic axis involving the immune activation of osteoblasts and the proliferation of AML cells via kynurenine and serum amyloid A (SAA).
Available acute myeloid leukemia treatments focus on targeting the tumor, which can lead to side effects in elderly patients and the emergence of therapy-resistant leukemic clones. Oncometabolism, the production of self-augmentative metabolites by cancer cells, employs the tumor microenvironment to sustain themselves. Therefore, patients need a treatment specifically targeting the tumor microenvironment that blunts leukemia progression.
This technology elucidates kynurenine and SAA as two main components in this molecular network of leukemia proliferation. Kynurenine is produced by AML cells which induce osteoblasts into a pro-inflammatory state, resulting in the production of SAA to increase production of kynurenine in a feed-forward mechanism. Overproduction of kynurenine amplifies this effect and enhances AML proliferation. Inhibition of this axis decreases leukemia burden on the microenvironment and overall progression of the disease.
This technology has been validated in mouse models of AML.
Patent Pending
IR 21282, 21283
Licensing Contact: Jerry Kokoshka